Table 7.
Survival Analyses of 36 Patients with Smoldering Multiple Myeloma
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| OS HR(95% CI) | P-value | OS HR(95% CI) | P-value | |
| Sex=male | 1.312(0.470–3.663) | 0.604 | ||
| Yes | ||||
| No | ||||
| Age | 1.874(0.750–4.680) | 0.179 | ||
| ≧65 years | ||||
| <65 years | ||||
| Higher BMPC | 0.942(0.337–2.628) | 0.909 | ||
| Yes | ||||
| No | ||||
| Higher LDH | 2.040(0.580–7.175) | 0.267 | ||
| Yes | ||||
| No | ||||
| Severe hypoalbuminemia | 1.818(0.671–4.925) | 0.239 | ||
| Yes | ||||
| No | ||||
| ALP>187.5IU/L | 6.951(1.710–28.252) | 0.007 | ||
| Yes | ||||
| No | ||||
| BNP≧700pg/mL | 8.871(2.732–28.811) | <0.001 | ||
| Yes | ||||
| No | ||||
| AL amyloidosis | 6.579(2.090–20.708) | 0.001 | 8.741(2.254–33.896) | 0.002 |
| Yes | ||||
| No | ||||
| Better ITE | 0.107(0.039–0.295) | <0.001 | 0.196(0.058–0.660) | 0.009 |
| Yes | ||||
| No | ||||
| Treatment regimen | 0.176(0.066–0.471) | 0.001 | 0.249(0.075–0.835) | 0.024 |
| With bortezomib | ||||
| Without bortezomib | ||||
Note: The bold font represents statistical significance.
Abbreviations, BMPC, bone marrow plasma cells ratio; D-S staging, Durie Salmon staging; BNP, brain natriuretic peptide; LDH, lactate dehydrogenase; ITE, Initial therapeutic effect; OS, overall survival; HR, hazard ratio.